Your browser doesn't support javascript.
loading
Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience.
Remy, Clotilde; Caron, Bénédicte; Gouynou, Celia; Haghnejad, Vincent; Jeanbert, Elodie; Netter, Patrick; Danese, Silvio; Peyrin-Biroulet, Laurent.
Afiliação
  • Remy C; Department of Gastroenterology, University Hospital of Nancy, F-54000 Nancy, France.
  • Caron B; Department of Gastroenterology, University Hospital of Nancy, F-54000 Nancy, France.
  • Gouynou C; NGERE (Nutrition-Génétique et Exposition aux Risques Environnementaux), U1256 INSERM, Université de Lorraine, F-54000 Nancy, France.
  • Haghnejad V; Department of Gastroenterology, University Hospital of Nancy, F-54000 Nancy, France.
  • Jeanbert E; Department of Gastroenterology, University Hospital of Nancy, F-54000 Nancy, France.
  • Netter P; NGERE (Nutrition-Génétique et Exposition aux Risques Environnementaux), U1256 INSERM, Université de Lorraine, F-54000 Nancy, France.
  • Danese S; Unit of Methodology, Data Management and Statistic, Nancy University Hospital, F-54000 Vandoeuvre-lès-Nancy, France.
  • Peyrin-Biroulet L; Ingénierie Moléculaire et Ingénierie Articulaire (IMoPA), UMR-7365 CNRS, Faculté de Médecine, University Hospital of Nancy, University of Lorraine, F-54000 Vandoeuvre-lès-Nancy, France.
J Clin Med ; 11(24)2022 Dec 08.
Article em En | MEDLINE | ID: mdl-36555913
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article